Patents Act 1990

Patents Act 1990
Title	Patents Act 1990
Enacted by	Parliament of the United Kingdom
Royal assent	1990
Status	amended

Patents Act 1990 is an Act of the Parliament of the United Kingdom that reformed United Kingdom patent law to implement provisions of the European Patent Convention, the Agreement on Trade-Related Aspects of Intellectual Property Rights, and harmonize with statutes in the Republic of Ireland and other European Union member states. The Act replaced much of the earlier Patents Act 1949 framework and interfaced with decisions of the European Court of Justice, the European Patent Office, and rulings from the House of Lords and the Supreme Court of the United Kingdom in matters of industrial property and innovation policy.

Background and Legislative History

The legislative origins trace to UK negotiations with the European Patent Office and the drafting of the European Patent Convention, which involved delegations from Germany, France, Italy, and Netherlands. Pressure from international agreements such as the World Trade Organization and the TRIPS Agreement accelerated reform, aligning UK law with jurisprudence from the Court of Justice of the European Union and case law from the Patent Office appeals including decisions influenced by litigants like SmithKline Beecham, GlaxoSmithKline, and Eli Lilly and Company. Parliamentary debate involved the Department of Trade and Industry and testimony from institutions including the Royal Society and the Chartered Institute of Patent Attorneys.

Key Provisions and Structure

The Act reorganized statutes into parts dealing with patentability, application procedure, rights conferred, and revocation, mirroring structures seen in the European Patent Convention and the statutes of the Republic of Ireland and Australia. It defined roles for the Comptroller General of Patents and established procedures interacting with the European Patent Organisation as well as domestic tribunals such as the Patents County Court and appellate channels to the Court of Appeal of England and Wales and ultimately the Supreme Court of the United Kingdom. Provisions also cross-referenced international instruments like the Paris Convention for the Protection of Industrial Property.

Patentability Criteria and Exceptions

The Act codified patentable subject matter standards that echo tests applied by the European Patent Office and courts such as the High Court of Justice; exclusions include certain medical methods and discoveries consistent with precedents from Roche Products and Merrell Dow Pharmaceuticals. Sections address novelty, inventive step, and industrial applicability informed by comparative jurisprudence from the German Federal Patent Court, the French Cour de cassation, and decisions involving firms such as Unilever and Siemens. Exceptions and defences reflected concerns raised by public bodies including the World Health Organization and charities such as Médecins Sans Frontières.

Application and Examination Procedure

Procedural rules set out filing, priority claims under the Paris Convention, and patent prosecution steps that coordinate with the European Patent Office search and examination phases; applicants from corporations like IBM, Microsoft, and Rolls-Royce routinely navigate priority claims and PCT international filings. The Act delineated timelines, opposition mechanisms akin to those used by the European Patent Office Boards of Appeal, and appeals to tribunals that involve practitioners from the Institute of Patent Attorneys and counsel who have appeared before the House of Lords and the Court of Appeal of England and Wales.

Rights, Enforcement and Remedies

Rights conferred include exclusive rights to prevent third-party exploitation, with remedies including injunctions, damages, and accounting ordered by courts such as the Patents County Court and the Chancery Division. Enforcement actions have involved multinational litigants like Samsung Electronics, Apple Inc., and Nokia, with procedural intersections with competition law authorities including the Competition and Markets Authority and case law referencing the European Commission. Defences such as experimental use and prior user rights were clarified in light of decisions involving entities like Cambridge University and Imperial College London.

Amendments and Subsequent Reforms

Subsequent amendments reflected developments from the European Union harmonization efforts and rulings by the Court of Justice of the European Union, and were influenced by policy work at the Intellectual Property Office (United Kingdom), consultations involving the CBI and the Federation of Small Businesses, and judgments referencing multinational firms such as Pfizer and Bayer AG. Later reforms intersected with debates over the Unified Patent Court and the Unitary Patent project involving parties from Spain, Poland, and Portugal.

Impact and Criticism

The Act reshaped the United Kingdom innovation landscape, affecting universities like Oxford University and University of Cambridge and industry sectors represented by AstraZeneca and BP. Critics from NGOs such as Oxfam and academics at institutions like London School of Economics argued the balance favored corporate rights over access concerns raised by World Health Organization debates, while business groups including the CBI and law firms such as Linklaters highlighted increased legal certainty and alignment with the European Patent Convention. The Act’s legacy continues to be evaluated in light of evolving international frameworks such as the WTO and regional initiatives like the European Union single market.

Category:United Kingdom patent law